![share_log](https://pubimg.futunn.com/20210416029208795164fdb91e7.jpg?imageMogr2/thumbnail/76x76!/ignore-error/1/format/webp)
Recursion Pharmaceuticals | 10-K: FY2023 Annual Report
Recursion Pharmaceuticals | 10-K: FY2023 Annual Report
Recursion Pharmaceuticals | 10-K:2023財年年報
牛牛AI助理已提取核心訊息
Recursion Pharmaceuticals, a clinical-stage TechBio company, has reported on its business developments and future plans, emphasizing its commitment to decoding biology to industrialize drug discovery. The company's Recursion Operating System (OS) is central to its mission, enabling the mapping and navigation of biological, chemical, and patient-centric relationships across over 50 petabytes of proprietary data. Recursion has highlighted its expansive pipeline of clinical and preclinical programs, transformational partnerships, and an industry-leading dataset designed to accelerate value creation through its pipeline, partnerships, and technology products. The company has entered into significant collaborations with Bayer and Roche-Genentech in oncology and neuroscience, and with Enamine to generate enriched compound libraries for drug discovery. Recursion's financing history includes a successful...Show More
Recursion Pharmaceuticals, a clinical-stage TechBio company, has reported on its business developments and future plans, emphasizing its commitment to decoding biology to industrialize drug discovery. The company's Recursion Operating System (OS) is central to its mission, enabling the mapping and navigation of biological, chemical, and patient-centric relationships across over 50 petabytes of proprietary data. Recursion has highlighted its expansive pipeline of clinical and preclinical programs, transformational partnerships, and an industry-leading dataset designed to accelerate value creation through its pipeline, partnerships, and technology products. The company has entered into significant collaborations with Bayer and Roche-Genentech in oncology and neuroscience, and with Enamine to generate enriched compound libraries for drug discovery. Recursion's financing history includes a successful IPO in April 2021, raising net proceeds of $462.4 million, and subsequent private placements in October 2022 and July 2023, raising additional funds for operations. The company's future plans include sharing Phase 2 data for its Cerebral Cavernous Malformation (CCM) and Neurofibromatosis Type 2 (NF2) clinical trials, initiating a Phase 2 study for Clostridioides difficile Infection (REC-3964), and submitting an IND for a novel target in HR-proficient ovarian cancers and other solid tumors. Recursion's strategic approach to cybersecurity, with oversight by the Audit Committee of the Board of Directors, includes a comprehensive risk management process informed by the NIST Cybersecurity Framework. The company's facilities, including its corporate headquarters and operations in Canada, are deemed adequate for current needs, with leases extending into the late 2020s and early 2030s.
臨床前階段科技生物公司遞歸製藥公司已發佈其業務發展及未來計劃,強調其將生物學解碼以產業化藥物發現的承諾。該公司的遞歸操作系統(OS)是其使命的核心,使其能夠在超過50PB的專有數據中進行生物學、化學和以患者爲中心的關係的映射和導航。遞歸公司強調了其廣泛的臨床和臨床前項目、顛覆性的夥伴關係和行業領先的數據集,旨在通過其管道、夥伴關係和技術產品加速價值創造。該公司已與拜耳和羅氏-幹細胞技術在腫瘤學和神經科學領域展開了重要合作,並與Enamine合作生成豐富的化合物庫用於藥物發現。遞歸的融資歷史包括2021年4月成功進行的IPO,籌集淨收益爲4.624億美元,以及2022年10月和2023年7月的後...展開全部
臨床前階段科技生物公司遞歸製藥公司已發佈其業務發展及未來計劃,強調其將生物學解碼以產業化藥物發現的承諾。該公司的遞歸操作系統(OS)是其使命的核心,使其能夠在超過50PB的專有數據中進行生物學、化學和以患者爲中心的關係的映射和導航。遞歸公司強調了其廣泛的臨床和臨床前項目、顛覆性的夥伴關係和行業領先的數據集,旨在通過其管道、夥伴關係和技術產品加速價值創造。該公司已與拜耳和羅氏-幹細胞技術在腫瘤學和神經科學領域展開了重要合作,並與Enamine合作生成豐富的化合物庫用於藥物發現。遞歸的融資歷史包括2021年4月成功進行的IPO,籌集淨收益爲4.624億美元,以及2022年10月和2023年7月的後續私募股份,爲運營籌集了額外的資金。該公司未來的計劃包括分享其腦組織中空血管畸形(CCM)和神經纖維瘤2型(NF2)臨床試驗的2期數據,啓動康斯特氏梭菌感染(REC-3964)的2期研究,並提交在HR-proficient卵巢癌和其他實體瘤中的新靶點的IND。遞歸對網絡安全的戰略方法,由董事會審計委員會監督,包括NISt網絡安全框架形成的全面風險管理流程。該公司的設施,包括其加拿大的企業總部和運營部門,被認爲滿足當前需求,並且租約延伸到2020年代後期和2030年代初。
有用
沒用
譯文內容由第三人軟體翻譯。
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了